Tagged with R

Saudi Arabia With MENA’s healthcare landscape evolving rapidly, Recordati is expanding its presence, particularly in Saudi Arabia and the GCC, where regulatory advancements and a growing focus on rare diseases are creating new opportunities. Khaled Elrefae, General Manager MENA, is leading efforts to accelerate patient access, strengthen local expertise, and shape the…

Puerto Rico Backed by world-class expertise, cutting-edge technology, and an ecosystem built on collaboration, the Medical Device Cluster is redefining what it means for Puerto Rico to be a global leader in medical innovation. From scaling high-precision manufacturing to pioneering workforce development, the island is setting new industry benchmarks. Puerto Rico is…

Puerto Rico Isla Frio provides state-of-the-art temperature-controlled storage solutions for pharma, among other industries. Founder Geoffrey Parrillo discusses the company’s efforts to adapt to the demands of the pharma industry, offering solutions such as FDA-approved validated rooms. He also outlines Isla Frio’s unique real-time tracking technology, weighs in on the steps Puerto Rico…

Switzerland SkyCell is at the forefront of a fundamental shift in pharmaceutical logistics, where AI, real-time monitoring, and sustainability are no longer optional but essential. As pharmaceutical supply chains grow more complex, the need for precision, resilience, and carbon-conscious innovation has never been greater. With AI-driven optimization redefining efficiency and risk…

Europe With the proposed Biotech Act, the European Commission (EC) is aiming to boost the EU biotech industry’s competitivity in the face of major rivals like the US and China. Tackling the EU bloc’s regulatory complexity and its barriers to funding is not an easy task, but biotech stakeholders eye the…

Europe Stefan Barbour describes how personal loss and a multicultural, healthcare-focused background have driven a lifelong commitment to access to medicines. Now leading BeiGene’s diverse 22-country Sub Region Europe, a grouping he built from scratch, Barbour outlines his leadership style that blends trust, accountability and “aggressive talent development;” and explains how…

APAC This week’s Asia healthcare and pharma roundup from PharmaBoardroom content partner Selesta covers China’s USD 36.2bn in outbound licensing agreements, Henlius & EssexBio meeting Phase III endpoints, Organon acquiring US rights of tocilizumab biosimilar from Biogen, GE Healthcare’s acquisition of Japan’s Nihon Medi-Physics, Wuxi Biologics’ disposal of vaccine facility to…

Puerto Rico The industry’s growing reliance on outsourcing and flexible service models means that the consulting business, including ours, will continue to thrive. There is a strong market demand for specialised support, and as companies look to streamline operations, services like ours are well-positioned to meet that need. ProQuality Network, founded by…

Sweden Even though the development of these treatments takes time, there are many capable people continuing to push the field forward. I believe that lecanemab, BioArctic, and others dedicated to this area will keep innovating, learning, and improving—ultimately leading to better outcomes for patients with Alzheimer’s. Lars Lannfelt, co-founder and board…

USA Peter Marks, the US FDA’s top official for vaccines and cell and gene therapies, has resigned. A survivor of the first Trump administration, when his office faced intense pressure to fast-track COVID vaccine approvals, Marks reportedly clashed with new Health and Human Services Secretary Robert F. Kennedy Jr. and his…

Italy A roundup of some of the biggest pharma and healthcare stories coming out of Italy, including the country’s ever-falling birth rate; Chiesi’s new manufacturing investment; Doc Generici’s rebrand to DOC Pharma; Menarini’s oncology partnership with Insilico Medicine, and Angelini’s brain health deal with Cureverse.   Italian drug maker Recordati boosts…

Saudi Arabia Rare diseases, by definition, only affect small patient populations. However, when the more than 7,000 known rare conditions are taken together, their impact on health, societies, and economies is enormous. Moreover, over 90 percent of rare diseases have no known treatment, and rare disease patients often face delayed diagnoses and…